Clinical and Translational Radiation Oncology (Aug 2018)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

  • M.T. Dillon,
  • Z. Boylan,
  • D. Smith,
  • J. Guevara,
  • K. Mohammed,
  • C. Peckitt,
  • M. Saunders,
  • U. Banerji,
  • G. Clack,
  • S.A. Smith,
  • J.F. Spicer,
  • M.D. Forster,
  • K.J. Harrington

Journal volume & issue
Vol. 12
pp. 16 – 20

Abstract

Read online

PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts. Keywords: Phase I, Radiosensitization, ATR inhibition, DNA damage response, Clinical trial